Massimo Group to Unveil New Warrior 1500 UTV at Equip Exposition and Showcase Next-Generation Product Platform at 2026 SEMA Show

Viking Therapeutics (VKTX) stock surged 36% after reporting positive obesity drug data, with VK2735 showing sustained weight loss with less frequent injections. The company's stock has outperformed Eli Lilly (LLY) and Novo Nordisk (NVO) over the past month. Analysts see significant upside for VKTX, with an average price target implying 131% upside. Viking aims to challenge established obesity drugs like Wegovy and Zepbound.

Adobe has launched its Premiere mobile video editing app for Android devices running Android 13 or later with at least 5GB of RAM. The free app includes multi-track editing, audio enhancement, and AI tools, with paid upgrades for extra features. Adobe aims to capture the growing market of mobile content creators.

Alphabet's Google has agreed to fund upgrades at Georgia Power's Vogtle and Hatch nuclear plants, adding 96 MW of capacity. The deal aims to address rising energy demands from AI data centers and local opposition to such facilities. Georgia Power estimates $900 million in benefits for customers over the units' lifetimes, pending regulatory approval.

Treace Medical Concepts (TMCI) reported five-year results for its Lapiplasty bunion-correction procedure, showing low radiographic recurrence rates and sustained patient-reported improvements. The study, involving 137 patients, aims to drive surgeon adoption. TMCI's Q2 revenue was $45.4M, down 4%, with a net loss of $15.9M. Hedge fund interest grew, with 18 funds holding the stock in Q2 2026.

General Motors (GM) is introducing new V-8 engines for its trucks despite the hybrid sales boom. GM's strategy aims to optimize profits from full-size trucks to offset costs from tariffs and EV write-downs. The company plans to add plug-in hybrids next year. GM's approach is seen as a calculated move, not a mistake, according to industry analysts.

Connect Biopharma (CNTB) reported mixed Phase 2 asthma trial results. Rademikibart missed the primary endpoint (p=0.153) but showed lung-function improvement (p=0.023). The company plans to use this measure in Phase 3. CNTB has $31.5M in cash but faces development costs. FDA feedback and funding are key uncertainties.